Compare Chevron Corp (CVX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Inovio Pharmaceuticals Inc — how do they compare? Chevron Corp trades at $181.91 (market cap $361.99B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Chevron Corp is far larger — about 3776.6× Inovio Pharmaceuticals Inc's market cap, and Chevron Corp pays a 3.92% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CVX | INO | |
|---|---|---|
Market Cap | $361.99B | $95.85M |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $2.87 |
52-Week Low | $146.72 | $1.05 |
Enterprise Value | $402.09B | $66.86M |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.
The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
